BAIYUNSHAN PH

874
12.6000.16% ( +0.020 )
Delay Closed: Nov 16, 16:08:11

Overview

BAIYUNSHAN PH (874)

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People’s Republic of China and interna...

Open
12.600
High
12.630
Low
12.560
Prev. Close
12.580
Volume
738.00K
Turnover
9.29M
Avg Price
12.586
Bid/Ask Ratio
-75.00%
Amplitude
0.56%
52wk High
19.537
Volume Ratio
0.79
Turnover Ratio
0.34%
52wk Low
12.520
HK Mkt Cap
2.77B
Market CapHKD
20.48B
P/ETTM
8.12
P/EDynamic
5.29
P/EStatic
--
EPSTTM
1.55
EPSDynamic
2.38
EPSStatic
--
BVPS
27.97
P/B
0.45
HK Shares
219.90M
Dividend YieldTTM
6.85%
DividendTTM
0.863
Shares
1.63B
Min lot size
2,000
Currency
HKD

BAIYUNSHAN PH Analyst Rating

View more

Forecast & Rating

Nov 4, 2026
Price forecast
HK$17.8441.59%
Forecast & RatingStrong buy
2analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Hong Kong trading saw the stock rise to HKD 12.63 in morning session (10:09 HKT), but afternoon weakness prevailed, with the high capped at HKD 12.60 and closing at HKD 12.60—flat versus the prior close of HKD 12.58. This intraday sell-off pattern underscores market concerns about fundamentals. Q3 results revealed net profit of HKD 462.88 million, down 46.66% year-over-year, despite operating revenue growing 8.19%, as margin erosion weighed on sentiment. Year-to-date, the stock has tumbled 30.58% from HKD 18.15 to current levels, now sitting just 0.64% above the 52-week low of HKD 12.52, signaling accumulation near multi-month lows. Valuation has compressed to P/E 8.12 and P/B 0.45—historic lows. Recent initiatives including pursuit of a strategic investor for its operations and subsidiary equity raises have done little to lift sentiment, suggesting the market awaits operational turnaround evidence rather than financial restructuring.

  2. Nov, 13

    Guangzhou Baiyunshan Pharmaceutical shares closed slightly lower at HKD 12.58 on November 13, down 0.87% from the prior close of HKD 12.69, bringing the stock to within 0.48% of the 52-week low of HKD 12.52 established on October 29—a fresh benchmark touched just two weeks prior. Year-to-date performance has deteriorated markedly by 30.69% from the year's opening price of HKD 18.15, and the shares now trade 38.33% below the 52-week high of HKD 20.4 set a year ago. Profitability pressures remain acute: Q3 earnings per share plunged 46.57% year-over-year to HKD 0.2851, while net profit contracted 46.66% to approximately RMB 462 million despite reasonable revenue growth of 8.19% to RMB 23.38 billion; net profit margin compressed to just 1.98%. Recent corporate initiatives—including an Extraordinary General Meeting and board approval of subsidiary share placement programs totaling up to RMB 6 billion—point to structural adjustments underway. Notably, current valuations are deeply discounted with PE of 8.11 and PB of 0.45, while offering an elevated dividend yield of 6.86%.

  3. Nov, 12

    Baiyunshan Pharmaceutical closed down around 1% to 12.69 HKD today, driven by intensifying profit deterioration. Q3 net income plummeted 46.66% year-over-year to HKD 463 million while earnings per share crashed 46.57% to HKD 0.2851, despite revenue growth of 8.19% to HKD 23.38 billion—net margin compressed to just 1.98%. The stock has tumbled 30.08% year-to-date and now trades just above its 52-week low of 12.52 HKD set on October 29, down 37.79% from the 20.40 HKD peak in November last year. Shares are trading below both the 20-day moving average of 12.993 HKD and 60-day moving average of 13.361 HKD. Valuation has compressed significantly: PE ratio stands at 8.18x with PB at 0.45x and dividend yield at 6.80%. The board recently approved a subsidiary capital placement of up to RMB 6 billion, signaling management confidence, though the profitability recovery trajectory remains uncertain.

  4. Nov, 11

    Baiyunshan declined 0.62% to HKD 12.82 today in quiet trading, with intraday trading ranging from morning high of 12.97 to afternoon lows around 12.82-12.85. Year-to-date the stock has fallen 29.37%, trading 37.16% below its 52-week high of HKD 20.4 and approaching its 52-week low of HKD 12.52, marking a sharp drawdown from historical levels. The board's recent approval of a subsidiary financing plan of up to RMB 6 billion signals company capital requirements. On the earnings front, Q3 revenue grew 8.19% year-over-year to HKD 23.38 billion, yet net income declined 46.66% to HKD 463 million, showing some moderation from Q2's 52.68% YoY drop; however, net margin further compressed to 1.98%. Trading at historically depressed valuations (PE 8.27, PB 0.46), the stock has failed to attract significant buyers, suggesting persistent doubts about near-term profit recovery.

  5. Nov, 9

    Baiyunshan's stock fell 1.3% today, closing at HKD 12.88 from a gap-up opening of HKD 13.30 at 9:30 AM, as the market continues to digest the third quarter's profit plunge. Net income in Q3 tumbled 46.66% year-over-year to HKD 463 million, following an even steeper 52.68% decline in Q2, despite revenue growing 8.19% to HKD 23.38 billion, signaling severe deterioration in profitability with Q3 net margin shrinking to just 1.98%. From a price perspective, the stock has slumped 36.86% from its 52-week high of HKD 20.4 and is hovering near the 52-week low of HKD 12.52, marking a 29.04% decline year-to-date. The stock has broken below both its 20-day moving average of 13.068 and 60-day moving average of 13.476, reflecting persistent bearish momentum. However, valuation metrics remain deeply depressed with a PE ratio of only 8.3 and PB ratio of 0.46, suggesting the market has already priced in a bleak forward outlook.

News